Expression of squamous cell carcinoma markers and adenocarcinoma markers in primary pulmonary neuroendocrine carcinomas

Applied Immunohistochemistry and Molecular Morphology

Volumn 21, Issue 4, 2013, Pages 292-297

  Masai, Kyohei ^a   Tsuta, Koji ^a   Kawago, Mitsumasa ^a   Tatsumori, Takahiro ^a   Kinno, Tomoaki ^a   Taniyama, Tomoko ^a   Yoshida, Akihiko ^a   Asamura, Hisao ^a   Tsuda, Hitoshi ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

immunohistochemical marker; lung; neuroendocrine tumor

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 7; DESMOCOLLIN; DESMOCOLLIN 3; NAPSIN A; PROTEIN; PROTEIN P63; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARCINOID; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG ADENOCARCINOMA; LUNG CARCINOMA; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PRIMARY PULMONARY NEUROENDOCRINE CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NEUROENDOCRINE; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 84880922756     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31826fd4f3     Document Type: Article

References (37)

1. World Health Organization. Histological Typing of Lung and Pleural Tumours. 3rd ed. Germany: Springer; 1999.
2. Travis WD, Brambilla E, Muller-Hermelink HK, et al. Pathology and Genetics: Tumors of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC; 2004.
3. Gould VE, Linnoila RI, Memoli VA, et al. Neuroendocrine cells and neuroendocrine neoplasms of the lung. Pathol Annu. 1983;18: 287-330.
4. Travis WD, Colby TV, Corrin B, et al. Histological Typing Of Lung And Pleural Tumours. 3rd ed. Berlin: Springer; 1999.
5. Vollmer RT, Ogden L, Crissman JD. Separation of small-cell from non-small-cell lung cancer. The South- eastern Cancer Study Group pathologists' experience. Arch Pathol Lab Med. 1984;108:792-794.
6. Loo PS, Thomas SC, Nicolson MC, et al. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol. 2010;5:442-447.
7. Terry J, Leung S, Laskin J, et al. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol. 2010; 34:1805-1811.
8. Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol. 2011;35: 15-25.
9. Kaufmann O, Fietze E, Mengs J, et al. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol. 2001;116:823-830.
10. Pelosi G, Fraggetta F, Pasini F, et al. Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung. Am J Surg Pathol. 2001;25:363-372.
11. Sholl LM, Long KB, Hornick JL. Sox2 expression in pulmonary non small cell and neuroendocrine carcinomas. Appl Immunohistochem Mol Morphol. 2010;18:55-61.
12. Monica V, Ceppi P, Righi L, et al. Desmocollin-3: A new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod Pathol. 2009;22:709-717.
13. Ueno T, Linder S, Elmberger G. Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. Br J Cancer. 2003;88:1229-1233.
14. Miyanaga A, Honda K, Tsuta K, et al. Diagnostic and prognostic significance of alternatively spliced ACTN4 variant for high-grade neuroendocrine pulmonary tumours. Ann Oncol. 2012. (In press).
15. Krunic AL, Garrod DR, Madani S, et al. Immunohistochemical staining for desmogleins 1 and 2 in keratinocytic neoplasms with squamous phenotype: Actinic keratosis, keratoacanthoma and squamous cell carcinoma of the skin. Br J Cancer. 1998;77:1275-1279.
16. Fukuoka J, Dracheva T, Shih JH, et al. Desmoglein 3 as a prognostic factor in lung cancer. Hum Pathol. 2007;38:276-283.
17. Sturm N, Lantuejoul S, Laverriere MH, et al. Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34bE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. Hum Pathol. 2001;32:918-925.
18. Camilo R, Capelozzi VL, Siqueira SA, et al. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas. Hum Pathol. 2006;37:542-546.
19. Ang DC, Ghaffar H, Zakowski MF, et al. Expression of squamous markers in lung adenocarcinoma: Clinicopathologic and molecular correlates, and implications for differentiation from squamous cell carcinoma. Mod Pathol. 2010;23:397A.
20. Hiroshima K, Iyoda A, Shida T, et al. Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: A morphological, immunohistochemical, and molecular analysis. Mod Pathol. 2006;19:1358-1368.
21. Wang BY, Gil J, Kaufman D, et al. p63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. Hum Pathol. 2002;33:921-926.
22. Bishop JA, Teruya-Feldstein J, Westra WH, et al. p40 (DNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol. 2012;25:405-415.
23. Pelosi G, Fabbri A, Rossi G, et al. A two-hit minimalist diagnostic algorithm based on p40 (deltaNp63) and TTF-1 immunostaining upon small biopsy/cellblock samples for differentiating main subtypes of non-small cell lung cancer and sparing material. J Thorac Oncol. 2011;6:S335-S336.
24. Au NH, Gown AM, Cheang M, et al. P63 expression in lung carcinoma: A tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol. 2004;12:240-247.
25. Sheikh HA, Fuhrer K, Cieply K, et al. p63 expression in assessment of bronchioloalveolar proliferations of the lung. Mod Pathol. 2004;17:1134-1140.
26. Gontan C, De Munck A, Vermeij M, et al. Sox2 is important for two crucial processes in lung development: Branching morphogenesis and epithelial cell differentiation. Dev Biol. 2008;317: 296-309.
27. Turner BM, Cagle PT, Sainz IM, et al. A new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med. 2012;136:163-171.
28. Broers JL, Ramaekers FC, Rot MK, et al. Cytokeratins in different types of human lung cancer as monitored by chain specific monoclonal antibodies. Cancer Res. 1988;48:3221-3229.
29. Chhieng DC, Cangiarella JF, Zakowski MF, et al. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens. Cancer. 2001; 93:330-336.
30. van De Molengraft FJ, van Niekerk CC, Jap PH, et al. OV-TL 12/30 (keratin 7 antibody) is a marker of glandular differentiation in lung cancer. Histopathology. 1993;22:35-38.
31. Nitadori J, Ishii G, Tsuta K, et al. Immunohistochemical differential diagnosis between large cell neuroendocrine carcinoma and small cell carcinoma by tissue microarray analysis with a large antibody panel. Am J Clin Pathol. 2006;125:682-692.
32. Jerome Marson V, Mazieres J, Groussard O, et al. Expression of TTF-1 and cytokeratins in primary and secondary epithelial lung tumours: Correlation with histological type and grade. Histopathology. 2004;45:125-134.
33. Johansson L. Histopathologic classification of lung cancer: Relevance of cytokeratin and TTF-1 immunophenotyping. Ann Diagn Pathol. 2004;8:259-267.
34. La Rosa S, Chiaravalli AM, Placidi C, et al. TTF1 expression in normal lung neuroendocrine cells and related tumors: Immunohistochemical study comparing two different monoclonal antibodies. Virchows Arch. 2010;457:497-507.
35. Kaufmann O, Dietel M. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology. 2000;36:415-420.
36. Tan D, Li Q, Deeb G, et al. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: A high-throughput tissue microarray and immunohistochemistry study. Hum Pathol. 2003;34:597-604.
37. Matoso A, Singh K, Jacob R, et al. Comparison of thyroid transcription factor-1 expression by monoclonal antibodies in pulmonary and nonpulmonary primary tumors. Appl Immunohistochem Mol Morphol. 2010;18:142-149.